Center on Health Equity & Access
Clinical
Health Care Cost
Health Care Delivery
Insurance
Policy
Technology
Value-Based Care

Free In-Person Regional Events Focused on Oncology and Population Health

All Coverage Event Coverage Interviews News

AJMC Journals Anniversary Author Forms Authors Nominate a Rising Leader Submit a Manuscript

Lp(a) and Cardiovascular Risk: Advancing Awareness, Testing, and Management in Clinical Practice : Episode 7

A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

April 7, 2025

Nihar Desai, MD, MPH
Nathan Wong, PhD

Opinion

Video

Experts discuss an example illustrating the association between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD) risk and explore how this example can inform our understanding of Lp(a) and ASCVD risk on a population level.

EP: 1.Lp(a) in ASCVD and Guideline Recommendations

EP: 2.Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis

EP: 3.The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis

EP: 4.Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease

EP: 5.Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime

EP: 6.How the Genetic Nature of Lp(a) Levels Influences Screening

Now Viewing

EP: 7.A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

EP: 8.The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

EP: 9.Evidence Supporting 2024 Guidance for Lp(a) Testing

EP: 10.Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing

EP: 11.Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing

EP: 12.FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels

EP: 13.The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies

EP: 14.Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment

EP: 15.Lp(a) Testing: Prevalence and Strategies to Improve Uptake

EP: 16.Implementing Lp(a) Testing in Health Systems: Lessons From Real-World Experience

EP: 17.Implementing Lp(a) Testing: Learning From LDL Testing and Considering Value-Based Care Models

EP: 18.Present and Looking to the Future: Lp(a) Testing and Atherosclerotic Disease Management

Video content above is prompted by the following:

Dr Wong, can you offer an example illustrating the association between Lp(a) levels and ASCVD risk?
How might Dr Wong’s example inform how we think about Lp(a) and ASCVD risk on a population level?

Related Content

Lindsey Valenzuela, PharmD, APh, BCACP – screenshot by AJMC

Where Do Pharmacists Add Value in Arrhythmia Care? Lindsey Valenzuela, PharmD

October 15th 2025

Article

Lindsey Valenzuela, PharmD, explains how value-based models empower a single pharmacist to manage multiple layers of these disease states.

What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD

August 5th 2025

Podcast

Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.

Listen

Anjali Vaidya, MD, FACC, FASE, FACP | Image Credit: Temple University Hospital

Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD

September 17th 2025

Article

New findings reveal sotatercept's significant benefits for right ventricular function and tricuspid regurgitation in pulmonary arterial hypertension.

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

May 30th 2024

Podcast

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

Listen